High-Tech Biotechnology fighting cancer
Continuous innovation, strong customer focus and creative problem solving have made ScheBo®• Biotech AG a worldwide leading manufacturer of unique products.
ScheBo® • Biotech AG
- worldwide distribution network
- exclusive and superior technologies and products
- innovative and unique clinical diagnostic products
- international research network
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
Focusing on results with faecal pancreatic elastase and faecal lactoferrin from clinical studies conducted at the Royal Hallamshire Hospital in Sheffield, Dr David Sanders discusses the clinical value of faecal diagnostic assays
ScheBo Biotech engineered her own rapid test for the detection of SARS-CoV-2 IgM and IgG antibodies from human whole blood, serum and plasma samples.
Scientists from Egypt present a new study for the use of M2-PK as a biomarker for screening of colorectal cancer in ‚The Egyptian Journal of Community Medicine’.
ScheBo Biotech engineered her own ELISA test for the quantitative determination of Calprotectin in stool samples.
ScheBo Biotech engineered her own ELISA test for the quantitative determination of Lactoferrin in stool samples.
Faecal Pancreatic Elastase 1 – The Gold Standard for Non-Invasive Exocrine Pancreatic Function Testing
… now also available as a rapid test
New innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening.